Invivyd, Inc.
Invivyd develops monoclonal antibodies against viral infectious diseases, beginning with SARS-CoV-2.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story
Invivyd develops monoclonal antibodies against viral infectious diseases, beginning with SARS-CoV-2.
November 2026
September 2026
August 2026